Analysts Set $18.50 Target Price for Osmotica Pharmaceuticals PLC (OSMT)

Osmotica Pharmaceuticals PLC (NASDAQ:OSMT) has received a consensus broker rating score of 1.33 (Strong Buy) from the three brokers that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. Osmotica Pharmaceuticals’ rating score has improved by 11.3% in the last three months as a result of a number of analysts’ ratings changes.

Brokerages have set a 1 year consensus price target of $18.50 for the company and are anticipating that the company will post $0.20 EPS for the current quarter, according to Zacks. Zacks has also assigned Osmotica Pharmaceuticals an industry rank of 56 out of 255 based on the ratings given to related companies.

Several equities analysts have recently weighed in on the stock. Wells Fargo & Co assumed coverage on shares of Osmotica Pharmaceuticals in a research note on Monday, November 12th. They issued an “outperform” rating and a $18.00 target price for the company. Royal Bank of Canada assumed coverage on shares of Osmotica Pharmaceuticals in a research note on Monday, November 12th. They issued an “outperform” rating and a $17.00 target price for the company. Barclays assumed coverage on shares of Osmotica Pharmaceuticals in a research note on Wednesday, November 14th. They issued an “overweight” rating for the company. Finally, Jefferies Financial Group assumed coverage on shares of Osmotica Pharmaceuticals in a research note on Monday, November 12th. They issued a “buy” rating for the company.

An institutional investor recently bought a new position in Osmotica Pharmaceuticals stock. JW Asset Management LLC acquired a new stake in Osmotica Pharmaceuticals PLC (NASDAQ:OSMT) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 225,000 shares of the company’s stock, valued at approximately $1,744,000. Osmotica Pharmaceuticals accounts for 1.3% of JW Asset Management LLC’s portfolio, making the stock its 13th biggest holding. JW Asset Management LLC owned about 0.44% of Osmotica Pharmaceuticals at the end of the most recent quarter. Institutional investors and hedge funds own 0.01% of the company’s stock.

OSMT opened at $7.85 on Tuesday. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.07 and a current ratio of 1.29. Osmotica Pharmaceuticals has a twelve month low of $6.21 and a twelve month high of $9.90.

Osmotica Pharmaceuticals Company Profile

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER to treat Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone to treat muscle spasms; and ConZip for pain, as well as women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods.

Featured Article: What is a Backdoor Roth IRA?

Get a free copy of the Zacks research report on Osmotica Pharmaceuticals (OSMT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply